Form 8-K Sage Therapeutics, Inc. For: Dec 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Sage Therapeutics (SAGE) PT Raised to $193 at Needham & Company
December 7, 2017 4:05 PM ESTNeedham & Company raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $193.00 (from $100.00) while maintaining a Buy rating.
Analyst Danielle Brill commented, "Phase 2 data in major depressive disorder (MDD) with oral '217 showed statistically and clinically meaningful reductions on the primary HAM-D... More
Sage Therapeutics (SAGE) PT Raised to $198 at Stifel
December 7, 2017 12:37 PM ESTStifel raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $198.00 (from $105.00) while maintaining a Buy rating.
"Results were notable for clean safety, fast onset and solid durability of effect," Walsh said. "Today's positive results, paired with November's positive P3 brexanolone results (note... More
UPDATE: Sage Therapeutics (SAGE) PT Raised to $280 at RBC Capital; Potential 'Game-Changing' Data and Takeover
December 7, 2017 12:24 PM EST(Updated - December 7, 2017 12:34 PM EST)
(updated to add analyst comments)
RBC Capital analyst Brian Abrahams raised his price target on Sage Therapeutics (NASDAQ: SAGE) to $280.00 (from $137.00) while maintaining an Outperform rating.
Abrahams said the Phase 2 data for '217 "showed a... More
